NCT03190967: T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

NCT03190967: T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

NCT03190967
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 99 Years (Adult, Senior)
Location of Metastases: Brain
Additional Notes:
Exclusions: Patients with known leptomeningeal metastatic disease or major symptoms or impairments related to brain metastases
https://ClinicalTrials.gov/show/NCT03190967